Windtree Therapeutics Delays Quarterly Report Filing

Windtree Therapeutics ( (WINT) ) has released a notification of late filing.

Windtree Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The primary reason for the delay is the additional time needed to finalize financial statements and related disclosures, which could not be completed without unreasonable effort and expense. The company anticipates filing the report within five calendar days following the prescribed due date. Preliminary financial results indicate a significant increase in net loss, primarily due to an impairment loss on intangible assets and a loss on debt issuance. These results are subject to change upon completion of the reporting process. Windtree Therapeutics is committed to ongoing compliance efforts, as indicated by the signature of President and CEO, Jed Latkin, on the notification.

Spark’s Take on WINT Stock

According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.

Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Recent corporate events provide a minor positive outlook, but overall, the stock presents considerable risks with limited upside potential without a substantial change in financial performance or market conditions.

To see Spark’s full report on WINT stock, click here.

More about Windtree Therapeutics

Average Trading Volume: 1,487,986

Technical Sentiment Signal: Sell

Current Market Cap: $2.3M

See more data about WINT stock on TipRanks’ Stock Analysis page.